While these GLP‐1 RAs drugs have become cornerstones in the treatment of obesity,6 their use in people with obesity who have T1D has gained attention due to potential benefits on obesity‐related complications, but there has also been an interest in reducing insulin dose requirements and improving glycaemic control.7 This evidence concerns the gene INS and type 1 diabetes mellitus.